Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Researchers’ discovery may revolutionize treatment of Lou Gehrig’s disease

A team of researchers from the University of British Columbia and the Vancouver Coastal Health Research Institute have found a key link between prions and the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease. The discovery is significant as it opens the door to novel approaches to the treatment of ALS.

20 Sep 2011

Diabetes and dementia, connection found

A new study revealed that people with diabetes may be at an increased risk of developing dementia. Scientists have suspected the link between the two diseases for several years, but several experts say this latest study highlights how treating preventable diseases like diabetes and obesity may be useful in preventing the onset of dementia.

20 Sep 2011

People with diabetes more likely to develop dementia

People with diabetes appear to be at a significantly increased risk of developing dementia, according to a study published in the September 20, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

20 Sep 2011

Common misconceptions about Alzheimer's disease

Alzheimer's disease, the most common form of dementia, continues to be an ongoing battle for millions of Americans. With an estimated 5.4 million Americans living with the disease and an annual cost of $183 billion, Dr. Gustavo C. Roman, director of the Nantz National Alzheimer Center at the Methodist Neurological Institute, addresses some common misconceptions about this devastating disease.

20 Sep 2011

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.

20 Sep 2011

Chronic diseases could cost $47 trillion over the next 20 years: Report

A latest report by the World Economic Forum (WEF) suggests that the global economic impact of the five leading chronic diseases -- cancer, diabetes, mental illness, heart disease, and respiratory disease - could reach $47 trillion over the next 20 years.

19 Sep 2011

Low-dose anticholinergic drugs do not appear to cause cognitive impairment in dementia patients

Researchers whose findings on the detrimental impact of some common medicines on elderly people were widely reported earlier in the summer have found that taking a few of these medicines does not appear to cause further cognitive impairment in those already suffering from dementia.

19 Sep 2011

NTNU genetic research shows best recipe to limit risk of lifestyle-related diseases

What should we eat? Answers abound in the international media, all of which rely on their interpretation of recent medical literature to come up with recommendations for the healthiest diet. But what if you could answer this question at a molecular level - what if you could find out how our genes respond to the foods we eat, and what this does to the cellular processes that make us healthy - or not? That's precisely what biologists at the Norwegian University of Science and Technology have done.

19 Sep 2011

Gamers solve molecular structure of retrovirus enzyme

Gamers have solved the structure of a retrovirus enzyme whose configuration had stumped scientists for more than a decade. The gamers achieved their discovery by playing Foldit, an online game that allows players to collaborate and compete in predicting the structure of protein molecules.

19 Sep 2011

Humour as effective as medication in treating agitation in dementia, research shows

...

18 Sep 2011

Reducing levels of protein FKBP51 may yield new antidepressant therapies

Decreasing expression of a protein associated with susceptibility to depression made old mice resistant to depressive-like behavior while improving their hormonal response to stress, a study led by researchers at the University of South Florida found. The lack of this protein, FKBP51, did not adversely affect their memory, learning, or basic motor functions.

17 Sep 2011

New insight into how nervous system regulates immunity

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science.

17 Sep 2011

Policies needed to prepare individuals, society for earlier diagnosis and high risk of Alzheimer's

The changing tide of Alzheimer's diagnosis presents new challenges to the public, physicians and lawmakers: if you could find out your Alzheimer's risk, would you want to know? How should doctors tell you your risk? And what does it mean for the many newly diagnosed Americans still in the workplace?

16 Sep 2011

Anavex announces ANAVEX pre-clinical data on Alzheimer's disease

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer's disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society.

16 Sep 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer’s disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society. The symposium is being held in Yokohama, Japan from September 15-17, 2011.

15 Sep 2011

International patient groups anxiously await start of Huntington’s trial

Prana Biotechnology Limited received a very positive reaction from international patient groups and researchers at this week’s World Congress on Huntington’s Disease in Melbourne. The company had a major presence at the Congress and the Prana team has held numerous meetings and conversations with patient groups and researchers.

15 Sep 2011

Alzheimer’s & You: prevention & treatment of dementia

Despite many promising leads, no drug has yet been found to slow or modify the debilitating, and ultimately fatal, progress of Alzheimer’s disease, the most common form of dementia. Within 20 years almost half a million Australians will suffer from dementia, by 2050 the number will double to one million.

15 Sep 2011

Memory lapses may indicate cognitive problems

Older individuals' complaints about memory lapses such as having trouble remembering recent events may indicate that they are experiencing cognitive problems that are greater than typical age-related changes.

15 Sep 2011

CHK Nutrition, NeuroResearch Clinics sign consent to halt sale of unapproved amino-acid products

The U.S. Food and Drug Administration announced that two Minnesota companies have agreed to halt distribution of amino-acid products marketed to treat a number of diseases, until requirements of the Federal Food, Drug, and Cosmetic Act are met.

15 Sep 2011

Telestroke appears to be cost-effective for rural hospitals

In a first of its kind study, researchers have found that using two way audio-video telemedicine to deliver stroke care, also known as telestroke, appears to be cost-effective for rural hospitals that don't have an around-the-clock neurologist, or stroke expert, on staff.

15 Sep 2011